Author

Robert J. Gray

h-index 5 View on Semantic Scholar

We have 3 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

An AI Model Identifies Chemotherapy Benefit in Node-Negative HR+/HER2- Breast Cancer Patients from TAILORx, a Phase 3 Randomized Clinical Trial

BACKGROUND The prescribing of adjuvant chemotherapy for patients with breast cancer must balance the survival benefit against treatment-related toxicities. TAILORx, a phase 3 randomized clinical trial, demonstrated that endocrine therapy alone was, on average, noninferior to chemoendocrine therapy for patients classifi...

Nancy Chan, Cerise Tang, D. Biswas et al. · medRxiv · 1 citation

Open access Aug 2026

ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L

Ulixertinib had no demonstrable evidence of clinical activity in this small, heavily pretreated population of patients with tumors harboring BRAF fusions, or with non-V600E, non-V600K BRAF mutations.

V. Subbiah, Feng-Min Zhao, R. Kudchadkar et al. · Clinical Cancer Research · 0 citations

Open access Aug 2026

Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay

Comparing AYAs with non-AYAs among patients having relapsed/refractory disease, no significant differences in SNV/indel prevalence were observed, but CCND1 amplifications were more prevalent in AYA breast cancer.

Hari Sankaran, Y. Kotliarov, Ying-Dong Zhao et al. · JCO Precision Oncology · 0 citations